CAM-A-dependent HBV core aggregation induces apoptosis through ANXA1.

Valerio Taverniti (1) , Laura Meiss-Heydmann (1) , Cloe Gadenne (1) , Hannah Vanrusselt , Dieudonné Buh Kum (2) , Fabio Giannone (3) , Patrick Pessaux (1, 3) , Catherine Schuster (1) , Thomas F. Baumert (1, 3, 4) , Yannick Debing , Eloi Verrier (1)

1 ITM - Institute for Translational Medicine and Liver Disease
2 Aligos Therapeutics, Inc., San Francisco, CA, USA
3 IHU Strasbourg - L'Institut hospitalo-universitaire de Strasbourg
4 IUF - Institut universitaire de France

Background & Aims Chronic HBV infection is the leading cause of liver disease and of hepatocellular carcinoma. The improvement of antiviral therapy remains an unmet medical need. Capsid assembly modulators (CAMs) target the HBV core antigen (HBc) and inhibit HBV replication. Although CAM-A compounds are well-known inducers of aberrant viral capsid aggregates, their mechanisms of action in HBV-hepatocyte interactions are poorly understood. Recently, we demonstrated that CAM-A molecules lead to a sustained reduction of HBsAg in the serum of HBV replicating mice and induce HBc aggregation in the nucleus of HBc-expressing cells leading to cell death. Methods The mechanism of action by which CAM-A compounds induce cell death was investigated using an HBV infection model, HBc-overexpressing HepG2-NTCP cells, primary human hepatocytes, and HBV replicating HepAD38 cells. Results We first confirmed the decrease in HBsAg levels associated with CAM-A treatment and the induction of cell toxicity in HBV-infected differentiated HepaRG cells. Next, we showed that CAM-A-mediated nuclear aggregation of HBc was associated with cell death through the activation of apoptosis. Transcriptomic analysis was used to investigate the mechanism of action driving this phenotype. CAM-A-induced HBc nuclear aggregation led to the upregulation of ANXA1 expression, a documented driver of apoptosis. Finally, silencing of ANXA1 expression delayed cell death and apoptosis in CAM-A-treated cells, confirming its direct involvement in CAM-A-induced cell death. Conclusions Our results unravel a previously undiscovered mechanism of action involving CAM-As and open the door to new therapeutic strategies involving CAM to achieve a functional cure in patients with chronic infections. Impact and implications: Chronic HBV infection is a global health threat. To date, no treatment achieves viral clearance in chronically infected patients. In this study, we characterized a new mechanism of action of an antiviral molecule targeting the assembly of the viral capsid (CAM). The study demonstrated that a CAM subtype, CAM-A-induced formation of aberrant structures from HBV core protein aggregates in the nucleus leading to cell death by ANXA1-driven apoptosis. Thus, CAM-A treatment may lead to the specific elimination of HBV-infected cells by apoptosis, paving the way to novel therapeutic strategies for viral cure.

Domaines: Médecine humaine et pathologie

Valerio Taverniti, Laura Meiss-Heydmann, Cloe Gadenne, Hannah Vanrusselt, Dieudonné Buh Kum, et al.. CAM-A-dependent HBV core aggregation induces apoptosis through ANXA1.. JHEP reports : innovation in hepatology, 2024, 6 (10), ⟨10.1016/j.jhepr.2024.101134⟩. ⟨hal-04757453⟩